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To the Editor: In a recent issue of Kidney International, Lin
et al.1 demonstrated that the advanced glycation end
products (AGE) induce the same signaling events in rat
mesangial cells as induced by high glucose culminating in
increased expression of fibronectin and transforming growth
factor-b1. They found that both high glucose and AGE
increase Ras-dependent and nicotinamide adenine dinucleo-
tide phosphate (reduced form) oxidase-mediated superoxide
production and subsequently induce cytosolic extracellular
signal-regulated protein kinase and nuclear c-Jun activation,
leading to extracellular matrix accumulation.
The cellular handling of glucose is different from that of
AGE, because the involved receptors and metabolic pathways
are completely different. Therefore, it is surprising that
glucose and AGE induce exactly the same signaling pathways
in mesangial cells. As high glucose can rapidly form
intracellular AGE,2 one probable explanation could be that
the high glucose-induced signaling events in the mesangial
cells were actually mediated by AGE derived from glucose in
the study by Lin et al.1 However, the experimental conditions
utilized by Lin et al. raise some serious concerns. Mesangial
cells were treated with very high concentrations of D-glucose
and AGE (35 mM and 100mg/ml, respectively), and the
findings were compared with those of the vehicle-treated
condition. Lin et al.1 neither included a control substance, like
L-glucose or mannitol as a control for D-glucose, or bovine
serum albumin as a control for AGE in the experiments, nor
did they test the effects of 5 mM glucose in the mesangial cells.
Therefore, it is uncertain whether the signaling pathways
induced by high glucose and AGE reflect the characteristics of
these substances or the same signaling pathways could be
induced simply by osmotic/toxic effect of any substance.
Another methodological issue that has also drawn our
attention is the measurement of 8-hydroxy-20-deoxyguano-
sine (8-OHdG) by immunoblotting. To our knowledge, the
antibody against 8-OHdG has not been tested for immuno-
blotting, and the DNA fragments containing the modified
base 8-OHdG in tissue homogenate is unlikely to be detected
as a specific band in immunoblot. Lin et al.1 demonstrated a
single band, but did not mention the approximate molecular
weight of the band they considered for 8-OHdG.
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We thank Dr Biswas et al.1 for their interest in our recently
published work of high glucose and advanced glycation end
products raise Ras- and extracellular signal-regulated
kinases-dependent fibronectin accumulation of mesangial
cells.2 Their comments reflect the multiple signal transduc-
tion pathways in high glucose and advanced glycation end
products induction of oxidative stress and renal fibrosis
factor expression in mesangial cells. To this interesting
issue, the protocols of in vitro advanced glycation end
products (100 lM)- and high glucose (35 mM)-stressed
mesangial cells have been well established. We would refer
them to some recently published articles.3–5 It is not
surprising then that high glucose and advanced glycation
end products share similar molecular mechanisms to induce
fibrosis factor expression when basal medium (10% fetal
bovine serum and Dulbecco’s modified Eagle’s medium
constituting 5 mM D-glucose) with or without 35 mM
mannitol do not raise superoxide burst in our study model.
We note immunohistochemically and by immunoblot-
ting exogenous superoxide dismutases alleviation of
8-hydroxy-20-deoxyguanosine levels in diabetic kidney in
vivo. The provided protein band corresponding to 26 kDa
is one of the evident oxidative damaged molecules
containing 8-hydroxy-20-deoxyguanosine immunoreactiv-
ities in the diabetic kidney homogenate. The study
emphasizes the early control of oxidative stress in
preventing diabetes-induced fibrosis-promoting factor
accumulation of renal tissue.
1. Biswas SK, Peixoto EBMI, de Faria JBL. Do advanced glycation end
products and glucose induce similar signaling events in mesangial cells?.
Kidney Int 2006 (in press).
2. Lin CL, Wang FS, Kuo YR et al. Ras modulation of superoxide activates
ERK-dependent fibronectin expression in diabetes-induced renal injuries.
Kidney Int 2006; 69: 1593–1600.
3. Singh R, Singh AK, Alavi N, Leehey DJ. Mechanism of increased
angiotension II levels in glomerular mesangial cells cultured in high
glucose. J Am Soc Nephrol 2003; 14: 873–880.
http://www.kidney-international.org l e t t e r t o t h e e d i t o r
& 2006 International Society of Nephrology
Kidney International (2006) 70, 1523–1527 1523
4. Xu D, Kyriakis JM. Phosphatidylinositol 30-kinase-dependent activation of
renal mesangial cell Ki-Ras and ERK by advanced glycation end products.
J Biol Chem 2003; 278: 39349–39355.
5. Yamaguchi S, Inagai Y, Okmoto T, Amano S et al. Advanced glycation end
product-induced apoptosis and overexpression of vascular endothelial
growth factor and monocyte chemoattractant protein-1 in human-
cultured mesangial cells. J Biol Chem 2002; 277: 20309–20315.
CL Lin1 on behalf of the authors
1Department of Nephrology, Chiayi Chang Gung Memorial Hospital,
Chiayi, Taiwan
Correspondence: CL Lin, Department of Nephrology, Chiayi Chang Gung
Memorial Hospital, 613 6 West Chai-pu Road, Putzu city, Chiayi, Taiwan.
E-mail: linchunliang@adm.cgmh.org.tw
Mortality risk for patients
receiving hemodiafiltration versus
hemodialysis
Kidney International (2006) 70, 1524. doi:10.1038/sj.ki.5001759
To the Editor: Canaud et al.1 reported a significant 35%
lower mortality risk with high-efficiency hemodiafiltration
(HDF) compared to low-flux hemodialysis. Patients on HDF
were slightly older, significantly heavier, and longer on renal
replacement therapy (higher co-morbidity). Thus, they were
possibly selected for HDF because of their higher risk profile.
We evaluated HDF data prospectively collected in EuCliD2
from 56 clinics in Czech Republic, Hungary, Italy, and UK, all
belonging to an International dialysis provider network. To
reduce bias related to different dialysis doses, only patients on
three times a week schedule achieving an eKt/VX1.20 were
considered. Out of 2564 prevalent patients, 394 were treated
with HDF and 2170 with hemodialysis over 12 months.
Similarly, patients on HDF were heavier (67.6 versus 65.9 kg,
P¼ 0.03) and longer on renal replacement therapy (6.6174.94
versus 4.9775.05 years, Po0.001); however, they were
significantly younger (52.7716.3 versus 59.7716.1 years,
Po0.001). Furthermore, they were more likely to be diabetic
(20.3 versus 18.3%) or affected by neoplasm (8.4 versus 6.7%).
High-flux polysulfone was usually used. Data on replacement
volume is not currently available but, as on-line HDF was
standard, volumes are likely to be high (15–25 l).
HDF resulted in a significant 42.7% reduction in mortality
risk (odds ratio: 0.573; 95% confidence interval: 0.377–0.873).
After adjustment for age, gender, co-morbidities, and time on
renal replacement therapy, mortality risk reduction was 35.3%
(odds ratio: 0.647; 95% confidence interval: 0.419–0.991) and
remained significant. In conclusion, our data confirm the
results of Canaud et al.1 However, epidemiological evaluations
have limitations. The potential survival benefit of HDF must
be tested by controlled clinical trials.
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Jirka et al.1 submit a very interesting letter confirming the
results recently reported with the International Dialysis
Outcomes and Practice Patterns Study.2 They observed a
35.3% reduction rate in mortality risk in online hemodia-
filtration (HDF)-treated patients belonging to an interna-
tional dialysis care provider (Fresenius Medical Care, Bad
Homburg, Germany), after adjustment for age, co-morbid-
ities, and time on dialysis. These data were prospectively
collected over 12 months through the European Clinical
Database (Euclid) network in 56 clinics. This database
includes 2564 prevalent hemodialysis patients, out of them
394 were treated by online HDF. Online HDF was
comparable in terms of efficacy to the high-efficiency
group of Dialysis Outcomes and Practice Patterns Study
with a 15–25 l fluid exchanged per session and a Kt/V
superior to 1.2. Today, it is not still well understood why
these convective therapies are superior to hemodialysis.
However, one can speculate that by enhancing both the
removal of middle molecules toxins (e.g., B2M) and the
biocompatibility of the dialysis system (ultrapurity of
dialysate, highly permeable synthetic membranes), these
methods improve substantially the efficiency and the
quality of the delivered treatment.3 As suggested by Jirka
et al.1 prospective controlled randomized studies hemo-
dialysis versus HDF are missing. This lack will be certainly
corrected with the three European ongoing studies on this
topic.4 This brief report is, nevertheless, a very strong
support to our findings showing that high-efficiency conve-
ctive therapies, such as online HDF, may offer an interesting
alternative to improve dialysis patient outcomes.
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